ARCHIVES

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

This article is from The Cancer Letter archive.

Vol. 39 No. 18 | May 8, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Jefferson Cancer Center Received $10 Million donation, Renamed Kimmel Cancer Center

March 29, 1996

Phase III PANORAMA-1 Trial Meets PFS Primary Endpoint

June 27, 2014

H. Lee Moffitt Center Reads The Cancer Letter

July 19, 2002

Bills Would Give FDA Authority to Approve Generic Biotech Drugs.

February 16, 2007

RFA Announcement On Carcinogenesis Extrapolation

August 1, 1980

Anidulafungin Safe And Well-Tolerated In Pediatric Patients With Neutropenia

November 26, 2004